Inhibitor Therapeutics (INTI) Income from Continuing Operations (2012 - 2026)
Inhibitor Therapeutics' Income from Continuing Operations came in at -$613,933 for Q2 2026, compared with -$659,942 a year earlier.
Powered by 
Analysis
Inhibitor Therapeutics (INTI) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Inhibitor Therapeutics reported Income from Continuing Operations of -$3.31 million; for FY2025, it came in at -$3.3 million.
- Going back by year, Income from Continuing Operations was -$3.34 million in FY2024, -$3.03 million in FY2023, $12.11 million in FY2022 and -$298,632 in FY2021.
- The Q2 2026 figure represents the highest quarterly Income from Continuing Operations since Q2 2024.
- Business Quant data shows INTI's Income from Continuing Operations at -$686,425 (Q1 2026), -$1.3 million (Q4 2025) and -$712,184 (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -246.00 Mn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Inhibitor Therapeutics | 17.38 Mn | 17.38 Mn | - | -613,933.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -613,933.00 |
| Mar 31, 2026 | -686,425.00 |
| Dec 31, 2025 | -1.30 Mn |
| Sep 30, 2025 | -712,184.00 |
| Jun 30, 2025 | -659,942.00 |
| Mar 31, 2025 | -632,846.00 |
| Dec 31, 2024 | -1.42 Mn |
| Sep 30, 2024 | -730,957.00 |
| Jun 30, 2024 | -501,690.00 |
| Mar 31, 2024 | -684,711.00 |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -664,760.00 |
| Jun 30, 2023 | -654,521.00 |
| Mar 31, 2023 | -539,596.00 |
| Dec 31, 2022 | -426,991.00 |
| Sep 30, 2022 | -77,692.00 |
| Jun 30, 2022 | -77,567.00 |
| Mar 31, 2022 | -98,910.00 |
| Dec 31, 2021 | -28,759.00 |
| Sep 30, 2021 | -66,248.00 |
API Access
Inhibitor Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=INTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "INTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=INTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();